Get started
Author

Salvador Fudio

A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients
2009 · E Ramirez, A J Carcas, et al. · Clinical Pharmacology & Therapeutics · 83
Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital
2010 · Elena Ramirez, Su H. Lei, et al. · Current Clinical Pharmacology · 77
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
2022 · Jose F Varona, Pedro Landete, et al. · Life Science Alliance · 61
PDF
Epileptic seizures caused by low valproic acid levels from an interaction with meropenem
2006 · S. Fudio, A. Carcas, et al. · Journal of Clinical Pharmacy and Therapeutics · 60
PDF
Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram
2009 · Salvador Fudio, Alberto M. Borobia, et al. · European Journal of Pharmacology · 56
Sublingual administration of tacrolimus in a renal transplant patient: Efficacy and safety of tacrolimus administration
2008 · I. Romero, C. Jiménez, et al. · Journal of Clinical Pharmacy and Therapeutics · 27
PDF
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
2018 · Carlos Fernandez-Teruel, Ignacio Gonzalez, et al. · Clinical Pharmacokinetics · 26
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
2018 · Elena Elez, Carlos Gomez-Roca, et al. · Investigational New Drugs · 22
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics
2022 · Salvador Fudio, Alvaro Sellers, et al. · Cancer Chemotherapy and Pharmacology · 15
Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer
2017 · L. van Andel, S. Fudio, et al. · Investigational New Drugs · 13
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas
2016 · Sandrine Aspeslagh, Mark Stein, et al. · Anti-Cancer Drugs · 12
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
2021 · Carlos Fernández-Teruel, Salvador Fudio, et al. · Cancer Chemotherapy and Pharmacology · 10
PDF
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine
2018 · L. van Andel, H. Rosing, et al. · Journal of Pharmaceutical and Biomedical Analysis · 9
PDF
Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine
2010 · C. De Dios, S. Fudio, et al. · Journal of Clinical Pharmacy and Therapeutics · 9
PDF
Interacción valproato-meropenem como ejemplo de las deficiencias en la información sobre interacciones farmacológicas clínicamente relevantes
2009 · Alberto M. Borobia, Salvador Fudio, et al. · Medicina Clínica · 9
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
2022 · María Victoria Mateos, Felipe Prosper, et al. · Cancer Medicine · 8
PDF
Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients
2022 · P. Aviles, R. Altares, et al. · Drug Metabolism and Disposition · 8
PDF
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
2021 · Yannis Metaxas, Carmen Kahatt, et al. · Investigational New Drugs · 6
Population Pharmacokinetic‐Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin
2021 · Carlos Fernández‐Teruel, Rubin Lubomirov, et al. · The Journal of Clinical Pharmacology · 6
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
2020 · Salvador Fudio, Josep Tabernero, et al. · Cancer Chemotherapy and Pharmacology · 6
Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin
2018 · L. van Andel, H. Rosing, et al. · Cancer Chemotherapy and Pharmacology · 6
PDF
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study
2024 · Irene Moreno, Tatiana Hernández, et al. · Marine Drugs · 5
PDF
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
2023 · Salvador Fudio, Laura Pérez-Ramos, et al. · Frontiers in Oncology · 5
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC–MS/MS
2023 · Nicholas King, Soledad Garcia-Martinez, et al. · PLoS ONE · 5
Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine
2017 · L. van Andel, H. Rosing, et al. · Journal of Pharmaceutical and Biomedical Analysis · 5
PDF
Works count: 43
Citation count: 578
H-index: 11
I10-index: 12
Year
Topic
Type